Setting
This study was performed in a region with a high prevalence of HIV and TB. A recent rise in diabetes cases led to the establishment of diabetes clinics to care for these patients. 9 The study included all the patients in the diabetes clinics in three hospitals in Western Kenya: Moi Teaching and Referral Hospital (MTRH) and two associated district hospitals, Webuye District Hospital (WDH) and Kitale District Hospital (KDH). MTRH is the second largest referral hospital in Kenya and serves the western region of Kenya. It serves both the urban population of Eldoret town, in which it is located, and the rural population of the surrounding region, as well as referral cases. WDH serves primarily a rural agricultural population, while KDH serves a peri-urban population.
Diabetes management
Patients in the three DM clinics were referred for diabetes care from a variety of sources: medical wards, medical out-patient clinics, health centers, dispensaries and community health workers. Clinical care was standardized across the three clinics. A standardized initial encounter form captured relevant information on enrollment: clinical, demographic, social and economic, including birth date, history of TB, HIV, cardiovascular disease and smoking. Standardized return visit forms were used during follow-up clinic visits to document vital signs, weight, height, random 
I
n three diabetes clinics in Western Kenya, a number of patients reported having a cough. Cough can be due to heart failure, chest infections, or the adverse effect of medications (angiotensin converting enzyme inhibitors) used in the management of diabetes mellitus (DM). More importantly, cough can be a marker for pulmonary tuberculosis (TB), a disease that is common in Kenya. 1 There is a strong association between TB and DM, with an estimated relative risk of 3.1 (95% confi dence interval [CI] 2.3-4.3) in one systematic review. 2 Few of the studies in the review were carried out in lowi ncome countries, and none in Africa. This raises uncertainties about the strength of the DM-TB association in these settings, and critical questions remain unanswered. 3 In sub-Saharan Africa, there have only been three studies on the co-morbidity of DM and TB. All were performed in Tanzania: two in 1990, one of which evaluated TB in patients with DM 4 and the other DM in patients with TB; 5 and the third in 2011, which evaluated DM in patients with TB. 6 The human immunodefi ciency virus (HIV) epidemic that emerged in the late 1980s signifi cantly increased the overall incidence of TB in countries in Public Health Action Important co-morbidity in DM patients 149 blood sugar/fasting blood sugar, glycated hemoglobin (HbA1c), symptoms, clinical fi ndings and medications prescribed during the visit. At the end of the patient encounter, the data were entered into an Access (Microsoft Corp, Redmond, WA, USA) database by trained staff.
Participants
The participants in this study were all patients with DM enrolled in the three clinics from January 2007 to February 2011, for whom information was available from the diabetes databases at the DM clinics.
Variables
A TB case was defi ned as a patient who had TB recorded in the DM clinic register, based on self-report. From these patients, we identifi ed those in whom TB was diagnosed at or after the diagnosis of DM. HIV status was based on self-report as recorded in the register. A smoker was defi ned as a patient who reported ever having smoked any form of tobacco.
Data collection
Data from the Microsoft Access database were collected by the data manager. 
RESULTS
Of 1519 patient records extracted from the database, 143 (9%) were excluded due to missing data. Data for 1376 patients were analyzed, of whom 750 (55%) were female. The mean age of the patients was 53. were on oral hypoglycemic agents and 495 (36%) on insulin. The remaining 229 patients (17%) had no treatment recorded in their charts, perhaps because they were not on treatment, or because it was omitted from their records. As this was a retrospective study, we were unable to determine the reasons. Of the 77 (5.6%) patients who reported a history of TB, 44 were diagnosed with TB after being diagnosed with DM. The only difference between patients with and those without TB was that a higher proportion of men (61%) than women (44%) had TB. There was no difference based on age, BMI, history of tobacco smoking or alcohol intake, type of diabetes medication or HbA1c level.
Only 414 (30%) patients reported knowing their HIV status; of these, 25 (6%) were HIV-positive. Of the 44 patients who were diagnosed with TB after DM, 29 knew their HIV status; 5 (17%) were HIV-positive.
Fifty-two (3.8%) patients reported a history of tobacco smoking; only one of these had a past history of TB.
DISCUSSION
This is the fi rst study in sub-Saharan Africa in 22 years to describe TB in diabetes patients. In addition, it refl ects the emergence of DM clinics in response to a rising tide of DM and the presence of important comorbidities, including TB (DM is a risk factor for TB), HIV (which is a prevalent health risk in these communities and a promoter of TB), and smoking. In this study in Western Kenya, 5.6% of the patients reported a history of TB, and only 30% of the patients knew their HIV status. In addition, we found a very low rate of tobacco smoking.
This study revealed new information about diabetes management in Kenya. Patients had been on treatment for an average of 8 years, with HbA1c levels and BMI remaining higher than accepted international targets. 10 However, these results are similar to those in many other countries in sub-Saharan Africa, where patients receive less than optimal care for their diabetes. 11, 12 Despite the generally poor diabetes control in this population, a third of our patients were on insulin therapy, and our clinics used HbA1c testing, indicating reasonable access to diabetes management tools.
In a setting with high HIV and TB prevalence, the co-morbidity of these infectious diseases in patients with DM is to be expected. Only a small proportion of this diabetic population had a past history of TB. These results may not refl ect the true burden of TB in DM due to the retrospective nature of the study and the stigma associated with TB in the past due to its association with HIV. In 1990, Swai et al. showed a 5.4% incidence of TB in Tanzania in a 7-year follow-up of 1250 diabetic patients. 4 Even though the true rate of TB might be higher, TB should be considered as an important co-morbidity of DM in this setting. The low rate of TB in this study does not support a policy of routine laboratory screening for TB, although patients presenting with symptoms compatible with TB should be investigated.
HIV is still an important public health issue in K enya. In our study, the proportion of patients who knew their HIV status, and were HIV-positive, was comparable to rates in the general Kenyan population. 13 However, the proportion of patients with a history of TB and who were HIV-positive was substantially higher (17%). This higher proportion could have been due to the fact that TB patients were more likely to have been tested for HIV at the TB clinics. 14 Patients are not systematically offered HIV testing in DM clinics, and only
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30% of the DM patients studied knew their HIV status. The DM clinic patients had an average age of >50 years, and their only contact with the health care system may have been the DM clinic, where HIV was not routinely tested. HIV screening, one of the principal strategies for the control of the HIV epidemic, should therefore be offered to all patients in the diabetes clinics and other chronic disease clinics in our setting. Tobacco smoking has been recognized as a major health problem in many settings worldwide. In 2004, a tobacco survey showed that 13.7% of adults in Kenya aged >18 years reported smoking tobacco (unpublished report). In this study, a relatively small proportion of patients, 3.8%, were tobacco smokers. We suggest this could be due to the cost of tobacco products, which may have been a deterrent to smoking among patients with many fi nancial obligations and limited resources. Furthermore, many patients in the rural setting chew and sniff tobacco, and no data on these forms of tobacco use were collected in the clinics.
The strengths of this study are that it is a cross-sectional look at the co-morbidity of TB, HIV and tobacco smoking in a new, emerging set of clinics caring for patients with DM. The study sample was large, and included all patients registered in the clinics over a 4-year period. It was also carried out under routine program conditions, and thus likely refl ected the situation in chronic disease clinics in Western Kenya. Finally, the study adhered to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. 15 The study had several limitations. One was the use of routine clinic data, which may have been inaccurate or had missing elements. However, only a small percentage of the clinic charts (9%) had to be excluded due to missing data. In addition, the study relied on recall of history of TB and HIV status, which may have been inaccurate. Although it is highly unlikely for a patient to forget a previous episode of TB, there could have been reporting bias (denial) due to associated stigma. TB has been associated with HIV in many clinical settings, and patients with DM may have declined to disclose a history of TB due to its association with HIV. In particular, patients could have inaccurately recalled the timing of diagnosis of TB and the timing of the onset of their diabetes. This could have led to an underestimation of the burden of TB attributable to DM. The poor diabetes control in this population could explain the failure to detect an association between TB and poor DM control, i.e., there were insuffi cient patients with good control to act as a comparison group for poor DM control as a risk factor for TB.
CONCLUSION
The rising prevalence of patients with DM in communities with a high prevalence of TB and HIV is bound to increase the comorbidity of these diseases and present new challenges for clinicians in sub-Saharan Africa. Further prospective studies are therefore necessary to better describe the co-morbidity between the two common infectious diseases, HIV and TB, with DM in our population. The frequency of HIV and TB in this cohort was comparable to that in the general population, with only a small proportion of patients reporting a history of tobacco smoking.
Contexte : Les polycliniques du diabète dans trois hôpitaux de l'Ouest du Kenya : Moi Teaching et Referral Hospital et deux hôpitaux de district associés. Objectif : Déterminer la proportion de patients diabétiques ayant des antécédents de tuberculose (TB), d'infection par le virus de l'immunodéficience humaine (VIH) et de tabagisme. Schéma : Etude descriptive utilisant les données colligées en routine dans les dossiers des patients dans les trois polycliniques du diabète. Résultats : On a analysé 1376 patients, parmi lesquelles 750 femmes (55%). L'âge moyen des patients dans les polycliniques a été de 53,5 années (IC95% 52,2-54,8), avec une durée moyenne du diabète de 8,1 années (7, (6) (7) (8) 7) . Sur l'ensemble des patients, 5,6% ont signalé des antécédents de TB, fréquence similaire à celle existant 20 ans plus tôt (1990) en Tanzanie. Seulement 30% des patients ont signalé connaître leur statut VIH et 6% ont été séropositifs pour le VIH. Des antécédents de tabagisme ont été signalés par 3,8% des patients. Conclusion : L'épidémie de VIH ne semble pas avoir modifié de manière significative les relations entre la TB et le diabète dans cette cohorte de patients diabétiques. La fréquence du VIH et de la TB dans cette population spécifique est comparable à celle observée dans la population générale ; une proportion faible seulement de patients signale des antécédents de tabagisme.
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